Parmantier & Cie. Initiates 'Buy' Rating on Clinuvel Pharmaceuticals Limited, Sets 12-Month Price Target at AU$26.50

Reuters

09/30

Parmantier & Cie. Initiates 'Buy' Rating on <a href="https://laohu8.com/S/CUV.AU">Clinuvel Pharmaceuticals</a> Limited, Sets 12-Month Price Target at AU$26.50

Parmantier & Cie. GmbH has issued a new research update on CLINUVEL Pharmaceuticals Limited, maintaining a "Buy" recommendation with a 12-month target price of AU$26.50. The report highlights CLINUVEL's strategic expansion in the US, including its planned upgrade to a Level II ADR program on Nasdaq by the end of 2025, aimed at increasing its visibility and attracting more institutional investors. Parmantier & Cie. also notes CLINUVEL's operational resilience, particularly its US-based manufacturing capacities, which protect the company from potential import tariffs and ensure robust supply chains. The research underscores CLINUVEL's strong positioning for sustainable international growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_23628), on September 30, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2571531763"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571531763\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571531763?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 16:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571531763","market":"us","top_or_hot":-1,"title":"Parmantier & Cie. Initiates 'Buy' Rating on Clinuvel Pharmaceuticals Limited, Sets 12-Month Price Target at AU$26.50","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Parmantier &amp; Cie. Initiates 'Buy' Rating on <a href=\"https://laohu8.com/S/CUV.AU\">Clinuvel Pharmaceuticals</a> Limited, Sets 12-Month Price Target at AU$26.50\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Parmantier &amp; Cie. GmbH has issued a new research update on CLINUVEL Pharmaceuticals Limited, maintaining a \"Buy\" recommendation with a 12-month target price of AU$26.50. The report highlights CLINUVEL's strategic expansion in the US, including its planned upgrade to a Level II ADR program on Nasdaq by the end of 2025, aimed at increasing its visibility and attracting more institutional investors. Parmantier &amp; Cie. also notes CLINUVEL's operational resilience, particularly its US-based manufacturing capacities, which protect the company from potential import tariffs and ensure robust supply chains. The research underscores CLINUVEL's strong positioning for sustainable international growth.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_23628), on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Parmantier & Cie. Initiates 'Buy' Rating on Clinuvel Pharmaceuticals Limited, Sets 12-Month Price Target at AU$26.50</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nParmantier & Cie. Initiates 'Buy' Rating on Clinuvel Pharmaceuticals Limited, Sets 12-Month Price Target at AU$26.50\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-30 16:52</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Parmantier &amp; Cie. Initiates 'Buy' Rating on <a href=\"https://laohu8.com/S/CUV.AU\">Clinuvel Pharmaceuticals</a> Limited, Sets 12-Month Price Target at AU$26.50\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Parmantier &amp; Cie. GmbH has issued a new research update on CLINUVEL Pharmaceuticals Limited, maintaining a \"Buy\" recommendation with a 12-month target price of AU$26.50. The report highlights CLINUVEL's strategic expansion in the US, including its planned upgrade to a Level II ADR program on Nasdaq by the end of 2025, aimed at increasing its visibility and attracting more institutional investors. Parmantier &amp; Cie. also notes CLINUVEL's operational resilience, particularly its US-based manufacturing capacities, which protect the company from potential import tariffs and ensure robust supply chains. The research underscores CLINUVEL's strong positioning for sustainable international growth.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_23628), on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CUV.AU","symbol_name":"CLINUVEL PHARMACEUTICALS LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL9fPGnt:1","article_id":"2571531763","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571531763","pubTimestamp":1759222345,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Parmantier & Cie. GmbH has issued a new research update on CLINUVEL Pharmaceuticals Limited, maintaining a \"Buy\" recommendation with a 12-month target price of AU$26.50. The report highlights CLINUVEL's strategic expansion in the US, including its planned upgrade to a Level II ADR program on Nasdaq by the end of 2025, aimed at increasing its visibility and attracting more institutional investors. Parmantier & Cie. also notes CLINUVEL's operational resilience, particularly its US-based manufacturing capacities, which protect the company from potential import tariffs and ensure robust supply chains. The research underscores CLINUVEL's strong positioning for sustainable international growth.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CUV.AU":"CLINUVEL PHARMACEUTICALS LTD","BK7508":"医药生物股","BK7067":"生物科技"},"translate_title":"帕尔曼蒂埃公司。对Clinuvel Pharmaceuticals Limited给予“买入”评级，将12个月目标价定为26.50澳元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CUV.AU":0.9},"content_text":"Parmantier & Cie. Initiates 'Buy' Rating on Clinuvel Pharmaceuticals Limited, Sets 12-Month Price Target at AU$26.50\n    \n\n        Parmantier & Cie. GmbH has issued a new research update on CLINUVEL Pharmaceuticals Limited, maintaining a \"Buy\" recommendation with a 12-month target price of AU$26.50. The report highlights CLINUVEL's strategic expansion in the US, including its planned upgrade to a Level II ADR program on Nasdaq by the end of 2025, aimed at increasing its visibility and attracting more institutional investors. Parmantier & Cie. also notes CLINUVEL's operational resilience, particularly its US-based manufacturing capacities, which protect the company from potential import tariffs and ensure robust supply chains. The research underscores CLINUVEL's strong positioning for sustainable international growth.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_23628), on September 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}